Skip to content

Filter by:

Keyword

Brummer C, Singer K, Henrich F, Peter K, Strobl C, Neueder B, Bruss C, Renner K, Pukrop T, Herr W, Aigner M, Kreutz M. The Tumor Metabolite 5′-Deoxy-5’Methylthioadenosine (MTA) Inhibits Maturation and T Cell-Stimulating Capacity of Dendritic Cells. Cells. 2024 Dec 20. 13doi:10.3390/cells13242114. PMID: 39768204

Barden M, Elsenbroich PR, Haas V, Ertelt M, Pervan P, Velas L, Gergely B, Szoor A, Harrer DC, Bezler V, Holzinger A, Friis RUW, Vereb G, Schutz GJ, Schoeder CT, Hombach AA, Abken H. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. J Immunother Cancer. 2024 Dec 2. 12doi:10.1136/jitc-2024-010208. PMID: 39622582

Simeth J, Huttl P, Schon M, Nozari Z, Huttner M, Schmidt T, Altenbuchinger M, Spang R. Virtual tissue expression analysis. Bioinformatics. 2024 Nov 28. 40doi:10.1093/bioinformatics/btae709. PMID: 39589902

Galletti G, De Simone G, Mazza EMC, Puccio S, Mezzanotte C, Bi TM, Davydov AN, Metsger M, Scamardella E, Alvisi G, De Paoli F, Zanon V, Scarpa A, Camisa B, Colombo FS, Anselmo A, Peano C, Polletti S, Mavilio D, Gattinoni L, Boi SK, Youngblood BA, Jones RE, Baird DM, Gostick E et al. Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans. Nat Immunol. 2020 Dec. 21:1552-1562. doi:10.1038/s41590-020-0791-5. PMID: 33046887

Denk A, Mittermaier C, Weber D, Fante M, Gunes S, Edinger M, Herr W, Wolff D. Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis. Ann Hematol. 2024 Sep. 103:3755-3764. doi:10.1007/s00277-024-05697-w. PMID: 38916742

Schelker RC, Fioravanti J, Mastrogiovanni F, Baldwin JG, Rana N, Li P, Chen P, Vadász T, Spolski R, Heuser-Loy C, Slavkovic-Lukic D, Noronha P, Damiano G, Raccosta L, Maggioni D, Pullugula S, Lin JX, Oh J, Grandinetti P, Lecce M, Hesse L, Kocks E, Martín-Santos A, Gebhard C, Telford WG, Ji Y, Restifo NP, Russo V, Rehli M, Herr W, Leonard WJ, Gattinoni L. LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling. Signal Transduct Target Ther. 2024 Aug 9;9(1):199. doi: 10.1038/s41392-024-01915-z. PMID: 39117617

Perl M, Herfeld K, Harrer DC, Hopting M, Schweiger M, Sterz U, Knodler L, Heimerl S, Hansmann L, Herr W, Poeck H, Wolff D, Edinger M, Hart C, Fante MA. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Haematologica. 2024 Sep 1. 109:2969-2977. doi:10.3324/haematol.2023.284564. PMID: 38546698

Schmidleithner L, Stuve P, Feuerer M. FOXP3 snatches transcription factors depending on the context. J Exp Med. 2024 Sep 2. 221doi:10.1084/jem.20240940. PMID: 38949640

Schreiber L, Ghimire S, Hiergeist A, Renner K, Althammer M, Babl N, Peuker A, Schoenhammer G, Hippe K, Gessner A, Albrecht C, Pielmeier F, Buttner-Herold M, Bruns H, Hoffmann P, Herr W, Holler E, Peter K, Kreutz M, Matos C. Strain specific differences in vitamin D3 response: impact on gut homeostasis. Front Immunol. 2024 15:1347835. doi:10.3389/fimmu.2024.1347835. PMID: 38495883

Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Volkl S, Hartley J, Dreger C, Petry K, Bosio A, von Dollen A, Hartmann W, Lode H, Gorlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. Clin Cancer Res. 2024 Aug 15. 30:3564-3577. doi:10.1158/1078-0432.CCR-23-3157. PMID: 38593230